Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Cardiovasc Pharmacol ; 42 Suppl 1: S71-4, 2003 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-14871033

RESUMO

This study compared the effects of amlodipine and valsartan on the sympathetic nervous system, the renin-angiotensin-aldosterone system, and brain natriuretic peptide, which are considered important parameters of the long-term prognosis. Seventy-three elderly patients, who had received antihypertensive treatment for more than 6 months with amlodipine, participated in this study. They were randomized to the V group (n = 36) and switched to valsartan from amlodipine, or to the A group (n = 37), which continued treatment with amlodipine. The dose of valsartan was set as that which controlled the blood pressure to the same extent as before switching. Blood samples were measured before and after 6 months of therapy. Data were analyzed by two-way analysis of variance with the Newman-Keuls test. In the V group, norepinephrine (from 597.0 +/- 52.9 to 475 +/- 43.8 pg/ml, p < 0.05) and aldosterone (from 74.5 +/- 7.0 to 53.9 +/- 5.3 pg/ml, p < 0.001) were decreased significantly after 6 months, although norepinephrine and aldosterone levels were unchanged in the A group. However, brain natriuretic peptide did not show a difference between the two groups. These findings suggested that valsartan is probably superior to amlodipine with respect to less activation of the sympathetic nervous system and preventing upregulation of the renin-angiotensin-aldosterone system.


Assuntos
Anlodipino/farmacocinética , Bloqueadores do Receptor Tipo 1 de Angiotensina II , Bloqueadores dos Canais de Cálcio/administração & dosagem , Preparações de Ação Retardada , Hipertensão/tratamento farmacológico , Neurotransmissores/fisiologia , Receptor Tipo 1 de Angiotensina/fisiologia , Tetrazóis/farmacocinética , Valina/farmacocinética , Idoso , Aldosterona/sangue , Anlodipino/administração & dosagem , Bloqueadores dos Canais de Cálcio/farmacocinética , Doença das Coronárias/complicações , Feminino , Insuficiência Cardíaca/complicações , Humanos , Hipertensão/complicações , Hipertensão/fisiopatologia , Masculino , Pessoa de Meia-Idade , Peptídeo Natriurético Encefálico/sangue , Neurotransmissores/sangue , Norepinefrina/sangue , Fatores de Tempo , Valina/análogos & derivados , Valsartana
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa